| [1] |
Members of the Breast Cancer Disease Site Group. The role of trastuzumab(Herceptin) in the treatment of women with HER2/neu-overexpressing metastatic breast cancer[EB/OL]. [2014-06-26].https:/ /www.cancercare.on.ca/pdf/pebc1-15f.pdf.
|
| [2] |
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med,2001,344(11):783-792.
|
| [3] |
Huober J, Fasching PA, Barsoum M, et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancerresults of the eLEcTRA trial[J]. Breast,2012,21(1):27-33.
|
| [4] |
Schwartzberg LS,Franco SX,Florance A,et al. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptorpositive metastatic breast cancer [ J]. Oncologist, 2010,15(2):122-129.
|
| [5] |
Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase ⅢTAnDEM study[J]. J Clin Oncol,2009,27(33):5529-5537.
|
| [6] |
Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer[J]. N Engl J Med,2012,366(2):109-119.
|
| [7] |
Blackwell KL, Miles D, Gianni L, et al. Primary results from EMILIA, a phase Ⅲstudy of trastuzumab emtansine (T-DM1)versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane[EB/OL]. [2014-06-26]. http:/ /meetinglibrary.asco.org/content/98675-114.
|
| [8] |
Verma S, Miles D, Gianni L,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer[J]. N Engl J Med,2012,367(19):1783-1791.
|
| [9] |
Andersson M, Lidbrink E, Bjerre K, et al. Phase Ⅲrandomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer:the HERNATA study[J]. J Clin Oncol,2011,29(3):264-271.
|
| [10] |
Valero V, Forbes J, Pegram MD, et al. Multicenter phase Ⅲrandomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer ( BCIRG 007 study): two highly active therapeutic regimens[J]. J Clin Oncol,2011,29(2):149-156.
|
| [11] |
Inoue K, Nakagami K, Mizutani M, et al. Randomized phaseⅢtrial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group[J]. Breast Cancer Res Treat,2010,119(1):127-136.
|
| [12] |
Gelmon KA, Boyle F, Kaufman B, et al. Open-label phase Ⅲrandomizedcontrolledtrialcomparingtaxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2 + metastatic breast cancer: Interim analysis(IA) of NCIC CTG MA.31/GSK EGF 108919 [ EB/OL]. [2014-06-26]. http:/ /meetinglibrary.asco.org/content/102986-114.
|
| [13] |
Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer[J]. J Clin Oncol,2010,28(7):1124-1130.
|
| [14] |
Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study[J]. J Clin Oncol,2012,30(21):2585-2592.
|
| [15] |
Cameron D, Casey M, Oliva C, et al. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase Ⅲrandomized trial[J]. Oncologist,2010,15(9):924-934.
|
| [16] |
Cameron D, Casey M, Press M, et al. A phase Ⅲrandomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses[J].Breast Cancer Res Treat,2008,112(3):533-543.
|
| [17] |
von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study[J]. J Clin Oncol,2009,27(12):1999-2006.
|
| [18] |
von Minckwitz G, Vogel P, Schmidt M, et al. Trastuzumab treatment beyond progression in patients with HER-2 positive metastatic breast cancer: the TBP study (GBG 26 / BIG 3-05)[ EB/OL ]. [ 2014-06-26 ]. http:/ /www. freecme. net/journalclub/abstract_breastcancer/Abstract_4056.html.
|
| [19] |
von Minckwitz G, Zielinski C, Maarteense P, et al.Capecitabine vs. capecitabine trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP phase Ⅲstudy (GBG 26/BIG 3-05)[EB/OL]. [2014-06-26]. http:/ /meeting. ascopubs.org/cgi/content/abstract/26/15_suppl/1025.
|
| [20] |
Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression[J]. J Clin Oncol,2004,22(6):1063-1070.
|
| [21] |
Wildiers H, Kim SB, Gonzalez-Martin A, et al. T-DM1 for HER2-positive metastatic breast cancer ( MBC): Primary results from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choice[C]/ / The European Cancer Congress,Amsterdam, the Netherlands, September 27-October 1,2013.Amsterdam: European Cancer Congress,2013.
|
| [22] |
Swain SM, Kim SB, Cortes J, et al. Confirmatory overall survival (OS) analysis of CLEOPATRA: A randomized,double-blind, placebo controlled Phase Ⅲ study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC) [EB/OL]. [2014-06-26]. http:/ /cancerres. aacrjournals. org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/P5-18-26.
|
| [23] |
Maxwell C. Quality-of-life considerations with taxane-based therapy in metastatic breast cancer[J]. Clin J Oncol Nurs,2013,17 Suppl:35-40.
|
| [24] |
National Cancer Institute. Breast cancer treatment (PDQ):Stage ⅢB, inoperable ⅢC, Ⅳ, recurrent, and metastatic breast cancer—Ado-trastuzumab emtansine[EB/OL]. [2014-06-26]. http:/ /www. cancer. gov/cancertopics/pdq/treatment/breast/healthprofessional/page6.
|
| [25] |
Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy[J]. J Clin Oncol,2010,28(7):1138-1144.
|
| [26] |
O'Shaughnessy J, Blackwell KL, Burstein H, et aL. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2 + metastatic breast cancer progressing on trastuzumab therapy[EB/OL]. [2014-06-26]. http:/ /meeting. ascopubs. org/cgi/content/abstract/26/15_suppl/1015.
|
| [27] |
Esteva FJ, Valero V,Booser D,et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer[J]. J Clin Oncol,2002,20(7):1800-1808.
|
| [28] |
Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage Ⅳnon-small-cell lung cancer[J]. J Clin Oncol,2009,27(36):6251-6266.
|
| [29] |
Fagerlin A, Zikmund-Fisher BJ, Ubel PA. Helping patients decide: ten steps to better risk communication[J]. J Natl Cancer Inst,2011,103(19):1436-1443.
|
| [30] |
Butow PN, Dowsett S, Hagerty R, et al. Communicating prognosis to patients with metastatic disease:what do they really want to know? [J]. Support Care Cancer, 2002, 10(2):161-168.
|